BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

Genentech and FDA's Center for Drug Evaluation and Research submitted summaries of what each considers the central questions to be presented and resolved at a June 28-29 hearing on FDA's proposal to withdraw metastatic breast cancer from the label of Avastin bevacizumab. Earlier in the month, the parties said in a joint statement they have been unable to agree on "the central questions that must be answered."...

Read the full 314 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >